Laboratorios Farmaceuticos Rovi Balance Sheet Health
Financial Health criteria checks 5/6
Laboratorios Farmaceuticos Rovi has a total shareholder equity of €543.5M and total debt of €65.4M, which brings its debt-to-equity ratio to 12%. Its total assets and total liabilities are €799.9M and €256.4M respectively. Laboratorios Farmaceuticos Rovi's EBIT is €219.5M making its interest coverage ratio -394.7. It has cash and short-term investments of €25.3M.
Key information
12.0%
Debt to equity ratio
€65.43m
Debt
Interest coverage ratio | -394.7x |
Cash | €25.32m |
Equity | €543.49m |
Total liabilities | €256.39m |
Total assets | €799.88m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0ILL's short term assets (€509.3M) exceed its short term liabilities (€199.8M).
Long Term Liabilities: 0ILL's short term assets (€509.3M) exceed its long term liabilities (€56.5M).
Debt to Equity History and Analysis
Debt Level: 0ILL's net debt to equity ratio (7.4%) is considered satisfactory.
Reducing Debt: 0ILL's debt to equity ratio has increased from 11.9% to 12% over the past 5 years.
Debt Coverage: 0ILL's debt is well covered by operating cash flow (173.1%).
Interest Coverage: 0ILL earns more interest than it pays, so coverage of interest payments is not a concern.